Search
Alzheimer's Disease Clinical Trials in Miami, FL
A listing of 29 Alzheimer's Disease clinical trials in Miami, FL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 29
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Alzheimer's Disease
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Miami, Florida, currently has 29 active clinical trials seeking participants for Alzheimer's Disease research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
ACP-204 in Adults With Alzheimer's Disease Psychosis
Recruiting
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP
* Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first.
* Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B wi... Read More
Gender:
ALL
Ages:
Between 55 years and 95 years
Trial Updated:
06/18/2025
Locations: Homestead Associates in Research Inc., Miami, Florida +7 locations
Conditions: Alzheimer's Disease Psychosis
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia.
The goals of this study are to learn:
* If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo
* About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
06/17/2025
Locations: Premier Clinical Research Institute ( Site 0114), Miami, Florida
Conditions: Alzheimer Disease, Dementia
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Recruiting
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
06/16/2025
Locations: Local Institution - 0022, Miami, Florida +1 locations
Conditions: Agitation, Alzheimer Disease
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
Recruiting
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/15/2025
Locations: Finlay Medical Research, Miami, Florida +1 locations
Conditions: Alzheimer Disease, Early Onset
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Recruiting
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease.
The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason and safety and tolerability in subjects wit... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
06/10/2025
Locations: Premier Clinical Research Institute - Miami - ClinEdge - PPDS, Miami, Florida +10 locations
Conditions: Psychosis Associated With Alzheimer's Disease
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Recruiting
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
06/09/2025
Locations: Homestead Associates in Research Inc, Miami, Florida +17 locations
Conditions: Alzheimer Disease
Clinical Trial on Agitation in Alzheimer's Dementia
Recruiting
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/09/2025
Locations: Global Medical Institutes Florida, LLC, Miami, Florida +1 locations
Conditions: Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
06/04/2025
Locations: VIN-Andrew Lerman, Miami, Florida +1 locations
Conditions: Alzheimer's Disease
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
Recruiting
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
06/04/2025
Locations: CCM Clinical Research Group, LLC, Miami, Florida +2 locations
Conditions: Alzheimer Disease
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
05/30/2025
Locations: Baptist Health South Florida & Florida International University, Miami, Florida
Conditions: Alzheimer Disease
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
Recruiting
The purpose of this research study is to test if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/27/2025
Locations: University of Miami Department of Neurology, Miami, Florida
Conditions: Alzheimer Disease, Agitation in Dementia
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Recruiting
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028.
The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
05/26/2025
Locations: Premier Clinical Research Institute - Miami - ClinEdge - PPDS, Miami, Florida +23 locations
Conditions: Psychosis Associated With Alzheimer's Disease
1 - 12 of 29